secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001628280-24-030243
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 reports positive Phase 2 mavorixafor data in chronic neutropenia; starts Phase 3 4WARD trial
--------------------------------------------------------------------------------

- 100% (6/6) evaluable participants achieved target ANC increase (>500 cells/µL) at Months 3 and 6 on mavorixafor ± G-CSF.
- Mavorixafor monotherapy achieved mean ANC ≥1,500 cells/µL at Months 3 and 6; severe CN patients had mean ANC ~800-1,000 cells/µL.
- Combination with stable-dose G-CSF increased mean ANC >1,000 cells/µL vs baseline at Months 1, 3, and 6.
- No drug-related serious adverse events; three discontinuations due to non-serious AEs.
- Global Phase 3 4WARD trial initiated (randomized, 150 patients, 52 weeks) for congenital, autoimmune, or idiopathic CN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024030243/0001628280-24-030243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024030243/xfor-20240627.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-030243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer